Q4 2025: Net sales of $540 million (+4% at actual rates, +1% at constant exchange rates (CER)); diluted EPS of $0.49 and adjusted diluted EPS of $0.62 Net sales growth of 1% CER ahead of outlook for steady results vs. Q4 2024, adjusted dilut... Read more
Dr. Albert Bourla, Chairman and CEO of Pfizer, said: “With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer’s foundation for future growth. Looking ahead, 2026 will be an important yea... Read more
Preliminary results for 2025: Group sales revenue rises by 7.6 percent to around 3.5 billion euros Positive development in both divisions: Significant sales revenue increase in recurring business with consumables; equipment and... Read more
As regulators worldwide intensify scrutiny of per- and polyfluoroalkyl substances (PFAS), laboratories are being pushed into a new era of sensitivity, speed, and scale. In this BioPharma BoardRoom interview, Craig Butt, PhD—an environmental s... Read more
Announces appointment of Claire M. Fraser, Ph.D., to its Board of Directors Forms a global life sciences and diagnostics leader focused on high-volume testing in regulated applications Announces formation of four divisions: Waters Analyti... Read more
Sharp Sterile Manufacturing has announced a $28 million expansion of its site in Lee, Massachusetts. The enhanced state-of-the-art facility will strengthen opportunities for highly skilled engineering and pharmaceutical manufacturing roles wi... Read more
The Seattle facility of AGC Biologics, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from Agência Nacional de Vigilância Sanitária (Anvisa), Brazil’s health regulatory authority. The a... Read more
Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it has successfully generated human induced pluripotent stem (iPS) cells from NKT cells and has begu... Read more
© 2026 Biopharma Boardroom. All Rights Reserved.
